

Table SI. Concomitant treatment regimens in the early discontinuation group (n=11) and in the all other patient group (n=29).

Treatment	Early discontinuation group, n (%)	All other patient group, n (%)
Chemotherapy, n (%)		
Platinum-doublet	0 (0)	5 (17)
ICI + platinum-doublet	1 (9)	1 (3)
Cytotoxic monotherapy	3 (27)	8 (28)
ICI monotherapy	0 (0)	4 (14)
Molecularly-targeted therapy	1 (9)	6 (21)
Chemoradiotherapy, n (%)	0 (0)	4 (14)
Best supportive care, n (%)	6 (55)	1 (3)

ICI, immune checkpoint inhibitor.